17 November 2026

Six BIA messages for London Life Sciences Week 2026 

Media briefing | BIA leaders, employees and members | 16 November 2026 

The UK life sciences sector combines influential science, global talent base and a focussed investment community. In 2026, year to date, the UK has grown VC life sciences investment by over 85% compared to all of 2025.  Now we must turn those strengths into companies that grow here, and into new medicines that reach patients. That is the opportunity we want investors and partners to back at London Life Sciences Week. 

1. World-class science 

The UK’s scientific strength is a compelling reason to invest here. Four of the top ten ranked universities in the world are based in the UK. The UK leads Europe in spin-outs from universities. Just over 10% of global medical sciences citations came from the UK in 2024. The UK has a science base that is internationally recognised as one of the strongest in the world 

See the THE 2026 Medical and Health rankings and the government’s Life sciences competitiveness indicators 2026. 

2. Regulation: world-leading regulator setting global standards of innovation and international collaboration 

A responsive, predictable regulator is a competitive advantage and crucial to the UK’s attractiveness as an international investment target and a destination of choice for developing new medicines.   

In 2025–26, the Medicines and Healthcare products Regulatory Agency (MHRA) approved 921 medicinal products and assessed 100% of clinical trial applications and national medicines licence applications within target timelines.  

See the MHRA announcement on its annual report. 

3. Data: translating a national strength into new discoveries 

The UK’s long-term investment in health and genomic data is a reason to build research partnerships here. The priority now is to turn that foundation into a service researchers can use. Alongside established research resources such as UK Biobank, the Health Data Research Service is backed by up to £600 million in committed funding: £100 million pledged by Wellcome and up to £500 million committed by the UK Government. The aim is to launch the first elements by the end of 2026, with further capabilities rolling out progressively.  

See Wellcome’s account of the funding and rollout. 

4. Creation and capital: build and grow biotech in the UK 

The UK is Europe’s leading destination for biotech venture capital. Our task is to turn that investor confidence into more UK companies that can scale here and serve the world from here. 

Latest BIA-verified proof point: UK biotech raised £3.35 billion in venture capital across 81 deals in the year to date as of the 9 November 2026, representing an increase of over 85%. This compares to £1.79 billion raised across 58 deals in the whole of 2025.  

Example — investment in AI-led drug discovery: In May 2026, Isomorphic Labs announced the largest UK VC investment ever recorded in the UK, a $2.1 billion Series B to develop and deploy its AI drug design engine, expand its therapeutic pipeline towards the clinic and support hiring across its sites.

See the company’s funding announcement. 

See BIA’s Q2 2026 financing report and 2025 financing report announcement. 

5. Medicines: the UK had more biotech-originated drugs approved in 2025 than any other European nation 

New, innovative medicines reaching patients must be the ultimate goal of backing UK life sciences. In 2025, nine UK originated drugs were approved for use in the US compared with six from Germany and one from France. Targeted support is needed to keep discoveries in the UK for development and commercialisation.  

Example — The UK leads Europe in Advanced Therapy Medicinal Products (ATMPs), hosting 193 ongoing ATMP clinical trials in 2025 (80% commercially sponsored) and recruiting roughly 9.5% of the world’s advanced therapy trial patients. 

Example — UK discovery reaching patient care: Capivasertib was discovered by AstraZeneca following a collaboration with Astex Pharmaceuticals and its work with the Institute of Cancer Research, London, and Cancer Research Technology. In May 2025, NICE recommended capivasertib with fulvestrant for adults with pre-treated HR-positive, HER2-negative locally advanced or metastatic breast cancer with certain genetic markers. See ICR’s account of the discovery pathway and NICE’s recommendation. 

6. Talent: investment in the people who turn science into businesses 

The UK’s scientific talent is a powerful foundation for biotech growth. As of July 2026, UK life sciences employs an estimated 360,000 people. We must keep strengthening that pipeline and developing the commercial leadership needed to build global businesses. 

BIA and the Francis Crick Institute’s PULSE programme provides leadership and entrepreneurship training for aspiring entrepreneurs and first-time CEOs, drawing on experienced CEOs, investors and industry professionals.  

BIA’s Manufacturing Advisory Committee (MAC) Leadership Programme, LeaP, develops emerging leaders in biopharmaceuticals and cell and gene therapy through site visits, mentoring, leadership sessions and collaborative projects. Together, these examples demonstrate an established industry workforce and practical routes to developing entrepreneurial and operational leadership. See the Government’s July 2026 workforce update, BIA’s PULSE programme and BIA’s MAC LeaP programme.